Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis-Reference-Cited by-同舟云学术

Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis

Published:2016-12-20 Issue:12 Volume:11 Page:e0168618
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chen Yingxi^ORCID,Liu Bette,Glass Kathryn,Du Wei,Banks Emily,Kirk Martyn

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference40 articles.

1. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome;MM Wolfe;Gastroenterol,2000

2. Overprescribing proton pump inhibitors;I Forgacs;BMJ,2008

3. Marked increase in proton pump inhibitors use in Australia;S Hollingworth;Pharmacoepidemiol Drug Saf,2010

4. The Pharmaceutical Benefits Scheme, PBS Statistics [Internet]. Australian Government Department of Health,. [cited 15 November 2015]. Available from: http://www.pbs.gov.au/info/browse/statistics#ASM.

5. Who is Using Chronic Acid Suppression Therapy and Why;BC Jacobson;Am J Gastroenterol,2003

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Burden and Cost of Campylobacter Risk Factors in Australia;Foodborne Pathogens and Disease;2024-08-29

2. Proton pump inhibitors and gastrointestinal symptoms among patients with COVID-19 infection;Annals of Medicine;2024-06

3. Case Report: The importance of early intervention for gastroesophageal reflex disease caused by hiatal hernia;Frontiers in Pediatrics;2024-05-13

4. Innovations in pharmacovigilance studies of medicines in older people;British Journal of Clinical Pharmacology;2024-03-26

5. Genomic and clinical characteristics of campylobacteriosis in Australia;Microbial Genomics;2024-01-12